<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02959502</url>
  </required_header>
  <id_info>
    <org_study_id>069/2016</org_study_id>
    <nct_id>NCT02959502</nct_id>
  </id_info>
  <brief_title>Home-Based CR and tDCS to Enhance Cognition in Persons With Mild Cognitive Impairment and Late Life Depression</brief_title>
  <official_title>Home-Based Cognitive Remediation and Transcranial Direct Current Stimulation to Enhance Cognition in Persons With Mild Cognitive Impairment and Late Life Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CAMH Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre for Addiction and Mental Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goals of this project are to assess the feasibility and impact of designing and
      implementing an at-home intervention aimed at preventing long-term cognitive decline and
      improving cognition in individuals currently at-risk for developing AD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By the time Alzheimer's Dementia (AD) and related disorders are diagnosed, the brain has
      sustained substantial insult that limits the efficacy of current treatments. Preventive
      interventions are urgently needed but the majority of prevention studies require large
      numbers of participants, long follow-up periods, and frequent study visits. It is not
      feasible for many geriatric patients to attend clinics for treatment on a daily basis due to
      mobility and transportation restrictions, associated costs, and lack of rural clinic
      locations. Interventions delivered remotely, or administered within an individual's home,
      allow for preventative treatments to be made accessible to a wider range of individuals.
      Thus, the overall goals of this project are to assess the feasibility and impact of designing
      and implementing an at-home intervention aimed at preventing long-term cognitive decline and
      improving cognition in individuals currently at-risk for developing AD. These high-risk
      individuals that will be targeted in this proposal are: (1) older adults with Mild Cognitive
      Impairment (MCI), (2) older adults with Major Depressive Disorder (MDD), and (3) older adults
      with MCI and MDD.

      The proposed intervention combines cognitive remediation (CR) and non-invasive brain
      stimulation - transcranial Direct Current Stimulation (tDCS), to be delivered in the
      participants' home environment. Twenty couples (40 participants) will be recruited, with one
      member defined as the &quot;patient&quot; and the second member defined as the &quot;caregiver&quot; to the
      patient. These caregivers will facilitate the delivery of the study intervention (i.e.,
      CR+tDCS). Participants with a diagnosis of MCI or MDD or both, who have a caregiver, will
      receive open-label, active CR+tDCS over a period of 8 weeks. Both CR and tDCS have been shown
      to induce neuroplasticity and improve cognition. The aim of this pilot study is to assess the
      feasibility of delivering these combined interventions at home.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of training a facilitator (caregiver) to facilitate the administration of CR+tDCS to their &quot;patient&quot; partner as indicated by a positive response in the Perceived Competence Scale at 24 months from study baseline.</measure>
    <time_frame>Approximately 24 months after baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess change in Quality of Life Scale scores among patients between baseline and at the end of the 8-week course.</measure>
    <time_frame>Baseline and 8 weeks after baseline.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure the change in Quality of Life Scale scores among facilitators between baseline and at the end of the 8-week course.</measure>
    <time_frame>Baseline to 8 weeks after baseline.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure the change in cognition (as indicated by a change in the Sheehan Disability Scale) among patients between baseline and at the end of the 8-week course</measure>
    <time_frame>Baseline to 8 weeks after baseline.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure the change in cognition (as indicated by a change in the Sheehan Disability Scale) among facilitators between baseline and at the end of the 8-week course</measure>
    <time_frame>Baseline to 8 weeks after baseline.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Major Depressive Disorder</condition>
  <condition>Alzheimer's Dementia</condition>
  <condition>Transcranial Direct Current Stimulation</condition>
  <condition>tDCS</condition>
  <arm_group>
    <arm_group_label>Receive tDCS + CR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive tDCS+CR: Over the course of 8 weeks, for 5 days a week, participants designated a 'Patient' will receive active tDCS &amp;CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory. Performance feedback is given to reinforce progress and the exercises are designed to be enjoyable to complete, with titrated difficulty levels over time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Facilitate tDCS + CR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Over the course of 8 weeks, for 5 days a week, participants designated a 'facilitator' will trained to deliver tDCS &amp;CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Receive tDCS+CR</intervention_name>
    <description>Over the course of 8 weeks, for 5 days a week, participants designated a 'Patient' will receive active tDCS &amp;CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory. Performance feedback is given to reinforce progress and the exercises are designed to be enjoyable to complete, with titrated difficulty levels over time.</description>
    <arm_group_label>Receive tDCS + CR</arm_group_label>
    <other_name>transcranial Direct Current Stimulation (tDCS)</other_name>
    <other_name>Cognitive Remediation (CR)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Facilitate tDCS + CR</intervention_name>
    <description>Over the course of 8 weeks, for 5 days a week, participants designated a 'facilitator' will be trained to deliver tDCS &amp;CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory.</description>
    <arm_group_label>Facilitate tDCS + CR</arm_group_label>
    <other_name>transcranial Direct Current Stimulation (tDCS)</other_name>
    <other_name>Cognitive Remediation (CR)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        MCI Group

        Inclusion:

          1. Age &gt; 60 (on day of randomization)

          2. DSM-IV criteria for Mild Neurocognitive Disorder (&quot;MCI&quot;)

          3. Willingness to provide informed consent

          4. MADRS score of 10 or below

          5. Availability of a study partner who has regular contact with the participant

          6. Ability to read and communicate in English (with corrected vision and hearing, if
             needed)

        Exclusion:

          1. Met DSM-IV criteria for Major Depressive Episode in past 10 years

          2. Lifetime DSM-IV diagnosis of schizophrenia, bipolar disorder, or OCD

          3. DSM-IV diagnosis of alcohol or other substances use disorder within the past 12 months

          4. High risk for suicide

          5. Significant neurological condition (e.g., stroke, seizure disorder, MS)

          6. Unstable medical illness, (e.g., uncontrolled diabetes mellitus or hypertension)

          7. Having taken a cognitive enhancer (acetylcholinesterase inhibitor or memantine) within
             the past 6 weeks

          8. Participants taking anticonvulsants, and other psychotropic medication (see exception
             below) that cannot be safely tapered and discontinued. The following psychotropic
             medications are allowed if they have been taken at a stable dose for at least 4 weeks
             prior to study entry: zopiclone, trazadone, or a benzodiazepine; gabapentin,
             pregabalin, duloxetine, venlafaxine, or low-dose tricyclic antidepressants if
             prescribed for chronic pain.

          9. A pace-maker or other metal implants that would preclude safe use of tDCS.

        MDD Group

        Inclusion:

          1. Age â‰¥ 60 (on day of randomization)

          2. Meets DSM-IV criteria for one or more MDE(s)with:

               1. an offset of 2 months to 5 years from the screening visit date. It is not
                  necessary for this (these) episode(s) to have received medical attention

                  OR

               2. an offset of 5 years or more from the screening visit date. It is necessary that
                  at least one MDE received medical attention (e.g., previously been on one or more
                  antidepressant(s), saw a psychiatrist, primary care physician, or had a previous
                  hospitalization). Also, the MDE must have occurred during the participant's adult
                  life (i.e., at 18 years of age or older).

          3. MADRS score of 10 or below

          4. Willingness to provide informed consent

          5. Availability of a study partner who has regular contact with the participant

          6. Ability to read and communicate in English (with corrected vision and hearing, if
             needed)

        Exclusion:

          1. Meets DSM-IV criteria for Major Neurocognitive Disorder (&quot;dementia&quot;)

          2. Lifetime DSM-IV diagnosis of schizophrenia, bipolar disorder, or OCD

          3. DSM-IV diagnosis of alcohol or other substances use disorder within the past 12
             months.

          4. High risk for suicide.

          5. Significant neurological condition (e.g., stroke, seizure disorder, MS)

          6. Unstable medical illness (e.g., uncontrolled diabetes mellitus or hypertension)

          7. Participants taking anticonvulsants, and other psychotropic medication (see exception
             below) that cannot be safely tapered and discontinued. In addition to any
             antidepressant, the following psychotropic medications are allowed if they have been
             taken at a stable dose for at least 4 weeks prior to study entry: zopiclone,
             trazodone, or a benzodiazepine; and gabapentin or pregabalin if prescribed for chronic
             pain.

          8. Having taken a cognitive enhancer (acetylcholinesterase inhibitor or memantine) within
             the past 6 weeks.

          9. A pace-maker or other metal implants that would preclude safe use of tDCS.

        Facilitator Group

        Inclusion:

          1. Willingness to provide informed consent

          2. Ability to read and communicate in English (with corrected vision and hearing, if
             needed)

             Exclusion:

          3. Physical or medical illness that prevents participant from learning or administering
             CR + tDCS, as determined by the research team
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tarek Rajji, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Addiction and Mental Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tarek Rajji, MD</last_name>
    <phone>416-535-8501</phone>
    <phone_ext>33661</phone_ext>
    <email>tarek.rajji@camh.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lillian Lourenco, MPH</last_name>
    <phone>416-535-8501</phone>
    <phone_ext>30409</phone_ext>
    <email>Lillian.Lourenco@camh.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6J 1H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarek Rajji, MD</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>33661</phone_ext>
      <email>tarek.rajji@camh.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.camh.net/research</url>
    <description>Information about research at the Centre for Addiction and Mental Health, Canada's largest mental health and addiction teaching hospital, fully affiliated with the University of Toronto, and a PAHO/WHO Collaborating Centre</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2016</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for Addiction and Mental Health</investigator_affiliation>
    <investigator_full_name>Tarek Rajji</investigator_full_name>
    <investigator_title>Chief of Geriatric Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

